Palvella Therapeutics closed at $162.28 on Nov 4, up 6.11% — matching its 52-week closing high. Volume of 407.4K shares was 1.71× its 20-day average (above normal).
Split-adjusted performance: +26.8% over one month, +24.7% over six months, +111.2% over one year.
Short interest was 2.4M shares at the Oct 15 settlement, down 4.6% from the prior report (21.7% of float, 9.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PVLAPalvella Therapeutics | $162.28 | +6.11% | +24.7% | — | — | — | $2.34B | |
| VERAVera Therapeutics | $31.97 | +4.10% | −12.6% | — | — | — | $2.30B | Compare |
| IMNMImmunome | $19.52 | −3.89% | −16.1% | −100.0% | — | — | $2.30B | Compare |
| BHVNBiohaven | $15.24 | −2.37% | +51.8% | — | — | — | $2.30B | Compare |
| AUPHAurinia Pharmaceuticals | $17.11 | +3.32% | +5.3% | +13.9% | 37.9% | 7.3 | $2.29B | Compare |
| SEPNSepterna | $47.88 | +9.57% | +93.8% | +22375.6% | −48.7% | — | $2.23B | Compare |
| TRLVTrulieve Cannabis | $11.60 | +0.52% | — | — | −149.8% | — | $2.23B | Compare |
| ZYMEZymeworks | $30.94 | +2.69% | +12.1% | −90.6% | −980.8% | — | $2.22B | Compare |
| RCUSArcus Biosciences | $19.31 | +2.12% | −25.7% | −74.4% | −222.0% | — | $2.46B | Compare |
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
